INTERESTED IN GETTING YOUR HANDS ON MONOCLONAL ANTIBODIES?
Click the image for more details
INNOVATORS
"Onco Med Pharmaceutical is a clinical stage company that discovers and develops novel therapeutics targeting cancer stem cells. The cells believed to be capable of driving tumor growth and more. A leader in cancer stem cell research, the company has establish a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such a pancreatic, breast, colorectal and lung cancers. Currently, they are waiting Phase 1 of clinical trials." |  |
 | "Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia. About 95% of CLL cases involve cancerous B cells that happen to crowd out the healthy cells, causing infection and/or symptoms. Campath targets these diseased blood cells for destruction." |
"Herceptin is a biologically engineered, monoclonal antibody designed to target and block the function of Human Epidermal growth factor Receptor 2. It is the first MAb-based therapy used to treat breast cancer, the second most common cancer in the world." |  |
 | "Rituxan help the B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as a single-agent maintenance therapy. This products help to fight agaisnt Non-Hodgkin's lymphoma which is a cancer that develops in the lymphatic system and Chronic Lymphoma disease." |
"Celltrion is a leading biopharmaceutical company in Korea specializing in monoclonal antibody capabilities that contribute to human life. It was established in 2002 with a goal to be the world's leading biopharmaceutical company in the Asian region. Celltrion has built a world-class facility, developed state-of-the-art technologies and established quality systems through active recruitment and investment in a short period of time." |  |
 | "BioArctic develops monoclonal antibodies for treatment of neurodegenerative diseases. The company's front-runner antibody BAN2401 was developed for treatment of Alzheimer´s disease with clinical trials on-going. Our technology is also applied to other CNS disorders such as Parkinson's disease. The antibodies developed have the unique property to reduce the toxic protofibrils, aggregated/misfolded proteins in the brain." |
"LeukoSite is a biopharmaceutical company located in Cambridge, MA. The company was founded in 1993 with the mission to become a sustainable multi-product pharmaceutical company focused on the discovery, development and commercialization of therapeutics for diseases of the immune system." |  |
Learn more about the many other monoclonal antibody innovators.
Click the image to view the video.
 |  |
